Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study,
showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free …

… of intercalated combination of chemotherapy and erlotinib versus … , the combination of
chemotherapy and erlotinib is a viable treatment option for patients with NSCLC, and intercalated …

… administration of chemotherapy and gefitinib or erlotinib on … intercalated chemotherapy with
afatinib or icotinib. … studies with intercalated chemotherapy plus EGFR-TKI combination in the …

… Citation 38 The possibility of a triple combination – intercalated regimen of cytotoxic and
targeted drugs with additional bevacuzimab – remains a challenge for future research. …

… 9 erlotinib plus standard first-line chemotherapy failed to … therapy with erlotinib and
chemotherapeutic agents and … that intercalated use of erlotinib and chemotherapy significantly …

… While recent studies suggest that combining first-line chemotherapy with the antiangiogenic
agent bevacizumab or the EGFR-directed monoclonal antibody cetuximab provide improved …

… To address the issue of the optimal schedule for combination of chemotherapy with TKIs,
we should understand why simultaneous therapy with both classes of drugs failed. An …

… the intercalated combination of EGFR-TKI plus chemotherapy … intercalated erlotinib versus
chemotherapy alone for patients with progressive NSCLC after clinical benefit from erlotinib, …

… Intercalated combination of chemotherapy and erlotinib for patients with advanced …
chemotherapy or erlotinib treatment. Thus, we suppose the intercalated chemotherapy and erlotinib …

… whether intercalated erlotinib with chemotherapy was superior compared to erlotinib alone
in … in selected EGFR patients and our results do support further exploration of combination …